Advertisement

Acta Neuropathologica

, Volume 129, Issue 1, pp 151–153 | Cite as

Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true “oligoastrocytoma”?

  • Jason T. Huse
  • Eli L. Diamond
  • Lu Wang
  • Marc K. Rosenblum
Correspondence

The current World Health Organization (WHO) classification system designates oligoastrocytoma as a diffusely infiltrating glial neoplasm exhibiting morphological features of both astrocytoma and oligodendroglioma [4]. Perhaps not surprisingly, a broad spectrum of diffuse gliomas having varying proportions of oligodendroglial and astrocytic character falls into this diagnostic category, with the classification of each tumor as astrocytoma, oligodendroglioma, or oligoastrocytoma suffering from significant inter-observer variability [9]. Recent large-scale molecular profiling efforts [1, 2, 3, 10] have emphatically confirmed earlier work [6] indicating that the vast majority of oligoastrocytomas, in addition to harboring mutations in IDH1/2, exhibit the signature genomic abnormalities of either pure oligodendroglioma (1p/19q codeletion, CIC and FUBP1 mutations) or astrocytoma (ATRX mutation, TP53mutation) with almost complete mutual exclusivity. Moreover, studies to date, including a...

Keywords

Astrocytoma Oligodendroglioma Diffuse Glioma Oligodendroglial Cell Oligodendroglial Component 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ et al (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32:783–790. doi: 10.1200/JCO.2013.49.3726 PubMedCrossRefGoogle Scholar
  2. 2.
    Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Marie SK et al (2012) Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722Google Scholar
  3. 3.
    Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, Heguy A, Petrini JH, Chan TA, Huse JT (2012) Whole exome sequencing identified ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3:1194–1203PubMedCentralPubMedGoogle Scholar
  4. 4.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart CG et al (2014) International society of neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (in press)Google Scholar
  6. 6.
    Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD et al (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161:313–319. doi: 10.1016/S0002-9440(10)64183-1 PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Qu M, Olofsson T, Sigurdardottir S, You C, Kalimo H, Nister M, Smits A, Ren ZP (2007) Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol 113:129–136. doi: 10.1007/s00401-006-0142-0 PubMedCrossRefGoogle Scholar
  8. 8.
    Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, Jones DT, Pfister SM, Herold-Mende C, Wick W et al (2014) Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 128:551–559. doi: 10.1007/s00401-014-1326-7 PubMedCrossRefGoogle Scholar
  9. 9.
    van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol 120:297–304. doi: 10.1007/s00401-010-0725-7 PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451. doi: 10.1007/s00401-013-1156-z PubMedCrossRefGoogle Scholar
  11. 11.
    Wilcox P, Li CC, Lee M, Shivalingam B, Brennan J, Suter CM, Kaufman K, Lum T, Buckland ME (2014) Oligoastrocytomas: throwing the baby out with the bathwater? Acta Neuropathol. doi: 10.1007/s00401-014-1353-4

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Jason T. Huse
    • 1
    • 2
  • Eli L. Diamond
    • 3
  • Lu Wang
    • 1
  • Marc K. Rosenblum
    • 1
  1. 1.Department of PathologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Human Oncology and Pathogenesis ProgramMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Department of NeurologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations